Navigation Links
FDA's Just Approved Monthly Drug Treatment, Vivitrol Could Be 'Game Changer,' Says Country's Largest Drug Treatment Recovery President, CRC's Jerry Rhodes; Provides Addicts 'One Decision A Month Instead of 30'
Date:10/12/2010

WASHINGTON and CUPERTINO, Calif., Oct. 12 /PRNewswire-USNewswire/ -- "The FDA's just approved monthly drug treatment with Vivitrol could be a game changer," said the country's largest substance abuse treatment provider, CRC Health Group, Recovery Division President Jerry Rhodes, whose company has 140 facilities across the country. Rhodes said the new treatment regimen "will provide addicts seeking help one decision a month instead of 30, and a new way to reduce or eliminate relapse. We are pleased to play a part in rolling out this potentially life-saving treatment."

Former U.S. Drug Czar, General Barry McCaffrey, now on CRC's Board, congratulated the FDA and CRC "for adopting a science-based new approach to reduce the national drug treatment gap. Addicts who in the past have been reluctant to seek treatment will be far more likely with a once-a-month opportunity to stop their craving. This is another important new tool in treatment."

Rhodes and McCaffrey offered "thanks and congratulations" to Alkermes Inc for developing and providing the medication approved today by the FDA and to be used by CRC facilities.

Rhodes stated that CRC has been utilizing Vivitrol to treat alcoholism "for years with extremely positive results" and is now in the process of developing the protocols and formulations for therapy for opiate patients. He stated that "every patient is an individual case. Vivitrol will be among the treatment options doctors will now have available, in addition to already existing Methadone and Suboxone (buprenorphine). In all cases, counseling and monitoring are a crucial part of treatment."

McCaffrey added, "The abuse of opioids like prescription pain medications and heroin is on the rise. Prescription drug abuse has tripled in the past decade – it's the new heroin. Nearly 16 million Americans ages 12 and older misused or abused prescription drugs or heroin in 2008 according to SAMHSA's National Survey on Drug Use and Health."

Contact: Bob Weiner 301-283-0821/202-306-1200 and Kristen Hayes 949-589-1765/562-229-2204


'/>"/>
SOURCE Robert Weiner Associates and CRC Health Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
3. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
4. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
5. Newly Approved HIV Drug Shows Great Promise
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
8. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
(Date:9/12/2017)... FRANCISCO , Sept. 12, 2017  ValGenesis ... Management Solutions (VLMS), is pleased to announce the ... a member of its Board of Directors and ... ValGenesis VLMS enables life science companies to manage ... the use of paper in this process. Furthermore, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
Breaking Medicine News(10 mins):